Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [HEALTH]

4 clusters · 10 sources · 48 days · First seen 2 months ago · Last updated 22 days ago

Pembrolizumab combo approvals and trial data

Overview

Since mid‑2026 the FDA and the EU have authorized pembrolizumab in combination with the HIF‑2α inhibitor belzutifan for adjuvant treatment of high‑risk clear‑cell renal cell carcinoma, and with the antibody‑drug conjugate en‑fortumab vedotin for neoadjuvant and adjuvant therapy of muscle‑invasive bladder cancer, regardless of cisplatin eligibility. Early trial evidence (LITESPARK‑022 and KEYNOTE‑905) showed substantial reductions in recurrence and mortality, prompting the regulatory actions.

A phase III international study (KEYNOTE‑B15/EV‑304) published in July 2026 added robust efficacy data for the en‑fortumab vedotin + pembrolizumab regimen. Among 808 patients, two‑year event‑free survival was 79.4 % versus 66.2 % with standard cisplatin‑gemcitabine, a 47 % risk reduction, and overall survival improved to 86.9 % from 81.3 %. The results were detailed in the New England Journal of Medicine by investigators Maria Kaparelou and Thanos Dimopoulos, confirming the survival benefits across a multinational cohort.

Concurrently, a safety trial at CU Anschutz Cancer Center is investigating abatacept with corticosteroids for checkpoint‑inhibitor‑associated myocarditis, highlighting ongoing efforts to manage cardiac toxicities as pembrolizumab‑based regimens expand across cancer types.

Entities

Enfortumab vedotin · Muscle‑invasive bladder cancer · KEYNOTE‑B15/EV‑304 · Pembrolizumab · Dr Maria Kapareli

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] The KEYNOTE‑B15/EV‑304 trial enrolled 808 patients with muscle‑invasive bladder cancer.
[● 3 SOURCES] Patients were randomized to receive enfortumab vedotin plus pembrolizumab before cystectomy or standard neoadjuvant chemotherapy with cisplatin and gemcitabine.
[● 3 SOURCES] The trial results were published in the New England Journal of Medicine.
[● 3 SOURCES] The study was conducted by Dr Maria Kaparelou and Prof Thanos Dimopoulos at the Alexandra Hospital, Medical School of the University of Athens (EKPA).
[● 2 SOURCES] Two‑year event‑free survival was 79.4 % with enfortumab vedotin‑pembrolizumab versus 66.2 % with chemotherapy.
[● 2 SOURCES] Two‑year overall survival was 86.9 % with the combination therapy versus 81.3 % with chemotherapy.
[○ 1 SOURCE] The improvement represented a 47 % reduction in the risk of recurrence, progression or death.

Timeline

22 days ago

[HEALTH] 3 sources
Enfortumab Vedotin‑Pembrolizumab Combo Boosts Survival in Muscle‑Invasive Bladder Cancer
Phase III KEYNOTE‑B15/EV‑304 showed that enfortumab vedotin + pembrolizumab yields 79.4% 2‑yr event‑free survival versus 66.2% with standard chemo, and 86.9% overall survival versus 81.3%, a 47% risk reduction.
about 1 month ago

[HEALTH] 2 sources
FDA approves Merck bladder cancer combo; trial tests abatacept for checkpoint inhibitor myocarditis
FDA green‑lights Merck’s pembrolizumab‑enfortumab combo for bladder cancer; CU Anschutz begins a trial of abatacept for checkpoint inhibitor‑related myocarditis.
about 2 months ago

[HEALTH] 3 sources
EU approves pembrolizumab‑enfortumab combo for bladder cancer
The EU has approved the pembrolizumab‑enfortumab vedotin combo as peri‑operative therapy for muscle‑invasive bladder cancer, citing KEYNOTE‑905 data showing 60% lower recurrence risk and 50% lower death risk.
2 months ago

[HEALTH] 3 sources
FDA approves belzutifan‑pembrolizumab combo for high‑risk kidney cancer
The US FDA approved the belzutifan‑pembrolizumab combination as adjuvant therapy for high‑risk clear‑cell renal cell carcinoma, citing a 28% drop in recurrence or death in the LITESPARK‑022 trial.

Sources

coloradocancerblogs.org · healthmag.gr · iatronet.gr · memesita.com · newshealth.biz · revistadafarmacia.com.br · stocktitan.net · world-today-journal.com · ygeiamou.gr · zougla.gr

This summary has been updated 1 time: see revision history